| 0.499 -0.009 (-1.77%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.73 | 1-year : | 0.87 |
| Resists | First : | 0.62 | Second : | 0.74 |
| Pivot price | 0.49 |
|||
| Supports | First : | 0.43 | Second : | 0.35 |
| MAs | MA(5) : | 0.5  |
MA(20) : | 0.49 |
| MA(100) : | 0.58 |
MA(250) : | 0.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48 |
D(3) : | 52.3 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 2.3 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SLRX ] has closed below upper band by 39.6%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.51 | 0.51 - 0.51 |
| Low: | 0.47 - 0.47 | 0.47 - 0.48 |
| Close: | 0.5 - 0.5 | 0.5 - 0.5 |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Mon, 25 Mar 2024
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket - Markets Insider
Mon, 25 Mar 2024
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday - Markets Insider
Mon, 25 Mar 2024
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket - Benzinga
Fri, 22 Mar 2024
Salarius: Q4 Earnings Snapshot - Houston Chronicle
Fri, 22 Mar 2024
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewswire
Fri, 23 Feb 2024
Salarius Pharmaceuticals Announces Executive Restructuring and Cost-Saving Measures - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 269 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -3.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76 % |
| Return on Equity (ttm) | -160.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|